Synairgen's inhalable drug fails study in hospitalised COVID patients
21/02/2022 07:35
Feb 21 (Reuters) - Britain's Synairgen SYNG.L said on
Monday its inhalable therapy failed an international late-stage
trial testing the drug in patients hospitalised with COVID-19,
leading a blow to the development of the drugmaker's key
product.
"While we are disappointed by the overall outcome, SNG001
has been administered to hospitalised patients on top of
standard of care which changed substantially between our Phase 2
and Phase 3 trials," Chief Executive Officer Richard Marsden
said referring to the treatment.
"This improvement in patient care may have compromised the
potential of SNG001."
(Reporting by Pushkala Aripaka in Bengaluru; Editing by
Subhranshu Sahu)
((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile:
+91 852 751 3793 ;))